Desoxymethyltestosterone is unusual in that it is structurally a 2-ene compound, lacking the 3-keto group present on nearly all commercial anabolic steroids. This does not mean it is a weak compound, and clinical research has determined that it is a fairly potent oral agent.  Rat studies indicate desoxymethyltestosterone has an anabolic effect 160% that of testosterone while being only 60% as androgenic giving it a Q ratio of :1.  Because of this favorable ratio, experiments in orchiectomised rats have demonstrated that treatment with desoxymethyltestosterone resulted only in a stimulation of the weight of the levator ani muscle; the prostate and seminal vesicle weights remained unaffected leading the authors of one study to characterize DMT as a powerful anabolic steroid with SARM (selective androgenic receptor modulator) attributes and some indication of toxicity. 
Amendments to Title 10 NYCRR Part 80 Rules and Regulations on Controlled Substances have been adopted and became effective as final regulations on August 27, 2013. The amendments specify the manner in which a practitioner must consult the Prescription Monitoring Program (PMP), and certain exceptions to that requirement. They clarify the practitioner's and pharmacist's ability to authorize a designee to consult the PMP on their behalf. The amendments change the frequency by which dispensing practitioners and pharmacies must submit dispensed controlled substance data to the Department of Health (Department), and include a requirement for reporting that no controlled substances were dispensed.